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Abstract
Background: Ventilator-associated pneumonia (VAP) is the most common infection in intubated critically ill
patients. Microaspiration of the contaminated gastric and oropharyngeal secretions is the main mechanism
involved in the pathophysiology of VAP. Tracheal cuff plays an important role in stopping the progression of
contaminated secretions into the lower respiratory tract. Previous in vitro studies suggested that conical cuff shape
might be helpful in improving tracheal sealing. However, clinical studies found conflicting results. The aim of this
study is to determine the impact of conical tracheal cuff shape on the microaspiration of gastric contents in
critically ill patients.
Methods/Design: This prospective cluster randomized controlled crossover open-label trial is currently being
conducted in ten French intensive care units (ICUs). Patients are allocated to intubation with a polyvinyl chloride
(PVC) standard (barrel)-shaped or a PVC conical-shaped tracheal tube. The primary objective is to determine the
impact of the conical shaped tracheal cuff on abundant microaspiration of gastric contents. Secondary outcomes
include the incidence of microaspiration of oropharyngeal secretions, tracheobronchial colonization, VAP and
ventilator-associated events. Abundant microaspiration is defined as the presence of pepsin at significant level
(>200 ng/ml) in at least 30 % of the tracheal aspirates. Pepsin and amylase are quantitatively measured in all
tracheal aspirates during the 48 h following inclusion. Quantitative tracheal aspirate culture is performed at
inclusion and twice weekly. We plan to recruit 312 patients in the participating ICUs.
Discussion: BEST Cuff is the first randomized controlled study evaluating the impact of PVC tracheal-cuff shape on
gastric microaspirations in patients receiving invasive mechanical ventilation. Enrollment began in June 2014 and is
expected to end in October 2015.
Trial registration: ClinicalTrials.gov Identifier: NCT01948635 (registered 31 August 2013).
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Background
Ventilator-associated pneumonia as a common intensive
care unit-acquired infection
Ventilator-associated pneumonia (VAP) is the most
common ICU-acquired infection in intubated critically
ill patients [1, 2]. VAP is associated with prolonged dur-
ation of mechanical ventilation, and ICU stay, increased
antibiotic use, mortality and additional cost [3–6]. During
the last decades, VAP prevention has become a major
quality-indicator in ICU patients [7, 8].
Microaspiration and pathogenesis of ventilator-associated
pneumonia
Microaspiration of gastric and oropharyngeal contami-
nated secretions represents the primary mechanism of
VAP pathogenesis [9–11]. Whereas microaspiration of
contaminated secretions is common in intubated critically
ill patients, many of them do not develop subsequent VAP.
Local and general defense mechanisms frequently prevent
the progression from tracheobronchial colonization to
ventilator-associated tracheobronchitis, and VAP. However,
when these mechanisms are insufficient and/or when
quantity and/or virulence of aspirated microorganisms are
high, lower respiratory tract infections develop in critically
ill patients [9].
Many risk factors for microaspiration have been identi-
fied and could be classified into those related to a tracheal
tube, to mechanical ventilation, to enteral nutrition, and
to the patient. Impossible closure of the vocal cords, longi-
tudinal folds in the PVC-cuffed tracheal tube, and under-
inflation of the tracheal cuff under 20 cmH2O are the
main factors related to the tracheal tube. Zero positive
end-expiratory pressure, low peak inspiratory pressure,
and tracheal suctioning are those related to mechanical
ventilation. Enteral feeding and nasogastric tubes are also
important risk factors for microaspiration because they
are associated with gastroesophageal reflux, gastric disten-
sion, and loss of the anatomic integrity of the lower
esophageal sphincter. Patient-related risk factors are su-
pine position, sedation and paralytic agents use, hypergly-
cemia, viscosity of the oropharyngeal secretions above the
cuff, tracheal diameter, and tracheal tube mobilization [9].
Pepsin derives from pepsinogen and is released from
the chief cells in the stomach [12]. Many animal and hu-
man studies have suggested that its presence in tracheal
secretions reflects gastric microaspiration in intubated
subjects [13–16]. Using pepsin as a marker of gastric
microaspiration in intubated critically ill patients is easy
to perform routinely. Benefits in using this quantitative
biomarker are that it is a noninvasive procedure and that
it offers the possibility to quantify microaspiration. Using
a quantitative marker to diagnose microaspiration is
important because VAP occurrence is closely correlated to
the amount of aspirated microorganisms [17, 18].
Evaluating the impact of preventive measures on
microaspiration of gastric contents is an interesting
strategy because microaspiration is more common than
VAP. Therefore, before performing large studies aiming
to determine the impact of a preventive measure on
VAP incidence, a study evaluating the impact of such a
measure on the incidence of microaspiration would
probably be helpful to confirm its efficiency.
Conical cuff shape and ventilator-associated pneumonia
Tracheal cuff shape seems to play an important role
in preventing microaspiration and VAP. A conical
(tapered)-shaped tracheal cuff insures a permanent
sealing zone between the external cuff diameter and
the internal trachea diameter, whatever the size and
the diameter of the trachea. This permanent contact
between the cuff and the trachea would prevent lon-
gitudinal folds and reduce microaspiration [19].
Three in vitro studies have examined the relation be-
tween conical cuff shape and fluid or air leakage [20–22].
Dave et al. demonstrated that there was no significant
difference between a polyurethane conical versus a cylin-
drical cuff on fluid leakage around the cuff when tracheal
diameter is small [20]. In contrast, conical shape was more
effective than cylindrical shape for reducing fluid leakage
in large-diameter tracheas. In another study, Zanella et al.
did not find any significant difference in fluid leakage be-
tween polyurethane conical versus cylindrical cuffs [22].
Madjpour et al. reported that conical-shaped PVC cuffs
improve air-sealing, compared with the PVC cylindrical
cuffs [21]. However, no significant difference was found
between conical versus cylindrical polyurethane cuffs. A
recent animal study evaluated the impact of PVC cuff
shape on fluid leakage, using methylene blue as a marker
for leakage. The authors concluded that leakage was sig-
nificantly reduced in animals intubated with conical-cuffed
tubes, compared with those intubated with cylindrical-
cuffed tubes [23].
D’Haese et al. performed a randomized controlled
study to evaluate the impact of conical cuff shape, com-
pared with barrel cuff shape, on microaspiration of blue
dye in 60 patients scheduled for lumbar surgery [24].
They reported that conical cuff shape was associated
with reduced leakage of dye diagnosed using fiberoptic
bronchoscopy. A recent multicenter randomized con-
trolled study evaluated the impact of polyurethane and/
or conical cuffs on tracheal colonization [25]. A total of
621 patients with an expected duration of mechanical
ventilation longer than 2 days were included with cuffs
composed of cylindrical PVC (n = 148), cylindrical poly-
urethane (n = 143), conical PVC (n = 150), or conical
polyurethane (n = 162). No significant difference was
found regarding the incidence of tracheal colonization
or VAP between the different study groups. However,
Jaillette et al. Trials  (2015) 16:429 Page 2 of 9
tracheobronchial colonization is probably not a good
marker for microaspiration because antibiotic treatment
might influence the rate of colonization. Whereas tracheo-
bronchial colonization mainly results from aspiration of
endogenous bacteria, contamination by exogenous bac-
teria is still possible [26, 27]. Several studies have shown
that exogenous contamination could result from contami-
nated aerosols, tracheal suctioning or flexible bronchos-
copy. Therefore, no definite conclusion could be drawn
based on the results of the TOP-cuff trial.
Study aim
The aim of this study is to determine the impact of a
PVC conical-cuffed tracheal tube, compared with a PVC
standard (barrel)-cuffed tracheal tube on abundant
microaspiration of gastric contents in patients with a
predicted duration of mechanical ventilation of at least
48 h. Secondary objectives include the impact of a
conical-shaped tracheal cuff on microaspiration of oro-
pharyngeal secretions, tracheobronchial colonization,
VAP, and ventilator-associated event (VAE) incidence.
Methods/Design
Design
BEST CUFF is a multicenter, cluster randomized cross-
over controlled and open-label trial performed in patients
receiving mechanical ventilation in the ICU. Because tra-
cheal intubation is an urgent procedure in ICU patients,
the randomization was performed on the participating
ICUs, and not on the patients. These ICUs were random-
ized into two balanced groups, according to an interven-
tion sequence. Using this design, half of ICUs are
randomized to use a PVC conical cuff (Fig. 1) in the first
1-month period and a PVC standard cuff (Fig. 2) in the
second 1-month period. The other half of the ICUs will
use the two interventions in the reverse sequence.
Each ICU recruits distinct subjects during the repeated
2-month periods using the assigned intervention se-
quence, meaning that each intervention sequence started
must be completed (Fig. 3).
Ethical aspects
The study protocol and patients (or next of kin) in-
formation documents were approved by the Ethical
Committee, and Institutional Review Board of the Lille
University Hospital (Comité de Protection des Personnes
Nord-Ouest, approved 2 July 2013, registration 2013
A00534 41).
Complete and fair information is provided to the
patient or to his representative. An informed written
consent is obtained before enrollment. When consent
is given by proxies, the patient is informed as soon as
possible, and his written consent is obtained.
Participating units
This study is currently conducted in ten French ICUs,
including three located in university hospitals and seven
in general hospitals.
Study population
Inclusion criteria are age ≥18 years, intubation in the
ICU with the study tracheal tube, an expected duration
of mechanical ventilation of at least 48 h after inclusion.
Exclusion criteria are age <18 years, pregnancy, patient
or proxy refusal, contraindication for enteral feeding, in-
tubation for >72 h at screening for eligibility in the trial,
tracheostomy at ICU admission, previous enrollment in
this study, or the inclusion in another study that may
interfere with this trial.
Fig. 1 Conical tracheal cuff
Fig. 2 Standard tracheal cuff
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Randomization
The randomization procedure (1:1 assignment interven-
tion sequence) was determined using a computer random-
number generator and was conducted by the Statistics De-
partment at Lille University Hospital (Lille, France) by a
person not associated with the study. The two interven-
tions studied are intubation using PVC conical-cuffed tra-
cheal tubes (TaperGuardR, Covidien, Astlone, Ireland)
and intubation using PVC standard (barrel)-cuffed tra-
cheal tubes (Hi-LoR, Covidien, Astlone, Ireland). When
reintubation is required, a tracheal tube with the same cuff
shape as the one used for the first intubation is used.
Definitions
Abundant microaspiration is defined by significant pepsin
level (>200 ng/ml) in >30 % of tracheal aspirates during
the 48 h following inclusion. This cut-off was calculated
based on the results of previous studies [13, 14].
Microaspiration of oropharyngeal secretions is defined
by the presence of alpha-amylase at significant level
(1800 UI/l) [28, 29] in tracheal aspirates. Tracheobron-
chial colonization is defined by positive endotracheal
sample without clinical and radiological signs of VAP.
VAP is defined as the presence of radiological and
clinical signs consisting of a new and persistent infil-
trate on the chest radiograph associated with two of
the three following criteria: purulent tracheal aspirates,
hyperthermia >38 °C or hypothermia <36 °C and periph-
eral leucocytosis >10,000/μl or <1,500/μl. A microbio-
logical confirmation is required using tracheal aspirate
≥105 CFU/ml or bronchoalveolar lavage ≥104 CFU/ml
[30]. Patients with only clinical and radiological signs
without microbiological confirmation are considered to
have a suspected VAP. Other ICU-acquired infections are
defined elsewhere [31].
Ventilator-associated events (VAE) are defined as a
sustained increase in ventilator support (minimum PEP
increase >2.5 cm H2O, or minimum FiO2 increase
>15 %) after >2 days of stable or decrease settings [32].
Patients with PEP >75 cm H2O or FiO2 > 70 % during
the first 3 days of mechanical ventilation are tested for
these VAC only if a higher stabilization is observed (PEP
<5 cm H2O, FiO2 < 40 % during >2 days).
Study protocol
Inclusions are performed 24 h/24 h, every weekday.
After inclusion, tracheal aspirates are collected for 48 h
to measure pepsin and amylase. When informed consent
is obtained <12 h after intubation, tracheal aspirates col-
lection is started at least 12 h after intubation (Fig. 4).
All tracheal aspirates are stored at -20 °C in each hospi-
tal’s laboratory, and subsequently sent to the central la-
boratory at the Lille University Hospital, where all
measurements of pepsin and amylase are blindly per-
formed. Quantitative measurement of pepsin is per-
formed by an ELISA technique, and salivary amylase
activity is calculated by the difference between total and
pancreatic amylase activity. The volume required to per-
form this analysis is 1 to 2 ml in each tracheal aspirate.
To diagnose tracheobronchial colonization, quantita-
tive tracheal aspirate is performed after intubation, and
two times a week. In patients with suspected VAP, quan-
titative tracheal aspirate or bronchoalveolar lavage is
performed to confirm the diagnosis. The choice between
tracheal aspirate culture or bronchoalveolar lavage is left
to the investigator’s discretion, based on routine practice
Fig. 3 Randomization in participating intensive care units (ICUs). CC, conical cuff; SC, standard cuff
Fig. 4 Timing of tracheal aspirate collection for pepsin and alpha-amylase measurements
Jaillette et al. Trials  (2015) 16:429 Page 4 of 9
in each ICU. Investigators prospectively follow patients
to detect clinical, radiological or microbiological signs of
suspected VAP or VAE. Patients will be followed until
ICU discharge or day 28, whichever happens first.
Care standardization
Cuff pressure is checked with a manual manometer
every 8 h and kept around 25 cm H2O. Patients are ven-
tilated in a semi-recumbent position. Female and male
patients are intubated with tracheal tubes sized 7.5 and
8 mm; respectively. Elevation of the head of the bed
is checked every 3 h. Oropharyngeal decontamination
is performed with 0.10 % chlorhexidine every 3 h.
Mechanical ventilation is performed with a positive
end-expiratory pressure of at least 5 cm H2O, except
when contraindicated. Weaning for mechanical ventilation
is checked every day to reduce the duration of tracheal in-
tubation. Systematic stress ulcer prophylaxis is not rou-
tinely recommended. The shortest duration of sedation is
recommended, using a nurse-driven protocol. Tracheal
suctioning is performed using an open system. Subglottic
secretion drainage is not used, and the respiratory circuit
is not routinely changed in study patients.
Data collections
At the time of inclusion, the following baseline characteris-
tics are recorded: age, sex, height, body weight, date of hos-
pital admission, date of ICU admission, patient location
before ICU admission (home, hospital for >24 h), date of
intubation and mechanical ventilation, preexisting comor-
bidities (diabetes and COPD, chronic restrictive respiratory
failure, chronic heart failure, cirrhosis Child B or C,
chronic renal failure, esogastroduodenal reflux, immuno-
suppression), McCabe score, Simplified Acute Physiology
Score II, SOFA score, and reason for the ICU admission.
At the time of randomization, the following character-
istics are recorded: SOFA score, duration of enteral feed-
ing before randomization, nasal or oral position of the
tracheal tube, cuff shape, and tube size.
During the 48 h following randomization, the variables
listed below are recorded: ventilatory mode, mean PEEP,
mean airway pressure, mean peak pressure, mean cuff
pressure, highest FiO2, nitric monoxide use, aerosols,
vasopressor support, enteral feeding volume, gastric re-
sidual volume, stress ulcer prophylaxis, use of prokinetic
agents, vomiting, sedation, neuromuscular blockers,
Glasgow Coma Score, mean head of bed elevation,
prone position, patient mobilization (on chair), patient
mobilization outside ICU room, accidental extubation,
reintubation, and death.
Until day 28 or until ICU discharge, the following
variables are being collected: sedation, transfusion,
tracheotomy, extubation failure, accidental extubation,
reintubation, shock, transport outside the ICU, mean
head of bed elevation, use of proton pump inhibitors,
ICU-acquired infection other than VAP (bacteremia,
ventilator-associated tracheobronchitis, intravascular
catheter-related infection, urinary tract infection, soft
tissue infection, and others), duration of antibiotic treat-
ment, duration of mechanical ventilation, length of ICU
stay, death, data related to VAE, pepsin and alpha-amylase
levels, VAP, and tracheobronchial colonization (Table 1).
Blinding
Blinding of physicians, nurses and patients is not feasible
in this study. However, pepsin and amylase measurements
are performed blindly. VAP diagnosis will be confirmed by
at least two independent blinded physicians.
Trial conduct and data monitoring
Before the start of patient enrollment, all physicians and
health-care workers received briefing on the study proto-
col and data collection in the electronic case report form
(eCRF). All documents required for this study are available
in each ICU in a folder dedicated to the study. Physicians
and/or a clinical research assistant are in charge of daily
patient screening and inclusion. The principal investigator
is available to all healthcare workers to answer all ques-
tions regarding the proper conduct of the study.
Study outcomes
Primary endpoint
The primary endpoint is the proportion of patients
with abundant microaspiration of gastric contents. This
Table 1 Study flowchart follow-up
Inclusion H12 to H72 Until Day 28 or ICU discharge Suspected VAP
Eligibility : check inclusion and exclusion criteria X
Randomization X
Quantitative TA culture X two times a week X
Pepsin and amylase measurement in all TA for 48 h X
Clinical and radiological signs of VAP X
Quantitative TA culture or BAL X
Clinical data X
ICU intensive care unit; TA tracheal aspirate; VAP ventilator-associated pneumonia; BAL bronchoalveolar lavage
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endpoint will be measured during the 48 h following in-
clusion in the study.
Secondary endpoints
The secondary endpoints include the following:
1. Proportion of tracheal aspirates positive for alpha-
amylase per patient
2. Proportion of patients with tracheobronchial
colonization, and bacterial concentration per patient
3. Proportion of patients with VAP
4. Proportion of patients with VAE
5. Proportion of patients with at least one ICU-
acquired infection
6. Antimicrobial-free days
7. Invasive mechanical ventilation-free days
8. Length of ICU stay
9. Proportion of patients who die in the ICU
The proportion of tracheal aspirates positive for alpha-
amylase per patient will be measured during the 48 h
following inclusion in the study. Other secondary end-
points will be measured from inclusion through day 28
or to final extubation if it happens before day 28.
Sample size
The main objective of this study is to demonstrate, in
intubated critically ill patients, the superiority of conical
cuff shape in reducing abundant microaspiration of gas-
tric contents, compared with standard cuff shape (con-
trol group). Based on previous studies [13, 14], the
expected incidence of abundant microaspiration of gas-
tric contents is 50 % in control group. We assumed that
the use of conical-cuffed tracheal tubes could reduce this
incidence to 30 % (that is, an absolute and relative risk
reduction of 20 % and 40 %, respectively). To detect this
effect size, with a two-sided alpha risk of 5 %, and a
power of 80 %, 90 patients would be required per group
in a conventional parallel-group randomized trial. Since
the experimental design is a cluster randomized cross-
over, we adjusted the study sample size to take into ac-
count the correlation between outcomes of patients
within ICU (namely intraclass correlation coefficient,
ICC) [33]. We did not take into account the inter-period
correlation (correlation between different patients in-
cluded within the same ICU but at different periods), in
order to maximize the statistical power. Using the for-
mula commonly used to plan a randomized cluster trial
by considering each ICU as a pool of two independent
clusters (one within each arm), assuming an ICC of
0.035 (corresponding to the upper quartile of ICC values
from 31 primary care researches) [34], an expected total
number of patients included per ICU of 30 patients, we
calculated that 140 patients would be required per
group. To account for an anticipated rate of 10 % of pa-
tients without any tracheal secretions, we planned to re-
cruit a total of 312 patients.
Statistical analysis
Statistical analyses will be independently performed by
the Biostatistics Department of University of Lille. Data
will be analyzed using the SAS software (SAS Institute
Inc, Cary, NC, USA), and all statistical tests will be per-
formed with a two-tailed alpha risk of 0.05. Statistical
analysis will be performed on an intention-to-treat basis.
A detailed statistical analysis plan will be written and
finalized prior to the database lock. The final report
will be written, based on the CONSORT statement
recommendations (Fig. 5).
Baseline characteristics will be compared between the
two study groups. Quantitative variables will be expressed
as mean (standard deviation), and median (interquartile
range). Qualitative variables will be expressed as frequen-
cies and percentages. Normality of distribution will be
assessed graphically and using the Shapiro-Wilk test.
Chi-square (or Fischer’s exact test), and Student t-test
(or Mann Whitney test) will be performed to compare
qualitative, and quantitative variables, as appropriate.
Primary endpoint
The proportion of patients with abundant microaspira-
tion will be compared between the two group using a
generalized linear mixed model including group as fixed
effect, and center and center*time period as the random
effects. Missing data for the primary endpoint are being
handled by multiple imputation using chained equations
(m = 10 imputations using primary endpoint and pa-
tient’s characteristics at inclusion).
Secondary endpoints
A generalized linear mixed model including group as the
fixed effect and center and center*time period as ran-
dom effects will also be used to compare each secondary
endpoints between the two groups. For quantitative end-
points, the normality of the model residuals will be
checked. In cases of non-normal distribution of residuals
(except if a log-transformation could be applied to
normalize the data), quantitative endpoints will be com-
pared using a Mann-Whitney U test.
Discussion
Whether the conical cuff shape of the tracheal tube is ef-
ficient in reducing microaspiration of contaminated oro-
pharyngeal and gastric secretions is unknown. Previous
clinical studies reported conflicting results [24, 25] and
had several limitations, precluding any definite conclu-
sion. Our study is sufficiently powered to detect a sig-
nificant difference in microaspiration of gastric contents
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between patients intubated with conical-cuffed tracheal
tube and those intubated with standard-cuffed tracheal
tubes. One of the strengths of this study is the use of
quantitative measurement of pepsin as a marker of
microaspiration. Pepsin is probably the most accurate,
currently available, marker for microaspiration [9].
Whereas technetium-99 is the gold standard for the
diagnosis of microaspiration of gastric contents [35], its
use is not allowed outside the Radiology Department.
The transport of critically ill patients outside the ICU
has a considerable potential for misadventure and could
be a life-threatening endeavor [36]. In addition, transport
outside the ICU was identified as a risk factor for
VAP [37]. Other markers for microaspiration, such as
blue dye, and tracheobronchial colonization have sev-
eral limitations, such as the qualitative measurement
of microaspiration and the presence of confounding
factors [9]. Alpha-amylase is a new marker for micro-
aspiration of oropharyngeal secretions. Two recent
studies [28, 38] reported promising results for its use
in patients with aspiration pneumonia and in small
cohorts of critically ill patients. However, our group
found a moderate accuracy of alpha-amylase in diagnosing
microaspiration compared with pepsin [29]. Further large
clinical studies should validate its accuracy in patients
with VAP.
We exclude patients with contraindication for enteral
nutrition and those with gastrostomy because these fac-
tors might influence the primary outcome. We aimed to
include patients early during invasive mechanical venti-
lation in order to increase the probability of them
remaining under invasive mechanical ventilation and to
have a complete period of 48 h during which tracheal as-
pirates are collected for pepsin and alpha-amylase
measurements.
Nevertheless, we start collection of tracheal aspirates for
pepsin measurements at least 12 h after intubation be-
cause this procedure is a well-known risk factor for micro-
aspiration. As pepsin half-life is relatively short (3 to 4 h),
this would probably allow a better interpretation of pepsin
measurement results.
Subglottic secretion drainage is an effective measure in
preventing VAP [39, 40]. However, this measure was not
clearly recommended when our trial was designed, and its
use was not generalized to all ICUs. In addition, one could
argue that it is probably more accurate to evaluate the effi-
ciency of these preventive measures, that is, the subglottic
secretion drainage and conical shape, separately.
Fig. 5 Flow diagram of Best cuff trial according to CONSORT
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If the study hypothesis is confirmed, further studies
should confirm the impact of conical cuff shape on the
incidence of VAP.
Trial status
Enrollment is ongoing. Inclusion started in June 2014. By
March 2015, 201 patients had been included. Recruitment
is expected to be complete in October 2015.
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